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Long-acting reversible contraception (LARC) is among the most effective contraceptive
methods, but uptake remains low even in high-income settings. In 2009/2010, a target-
based pay-for-performance (P4P) scheme in Britain was introduced for primary care physi-
cians (PCPs) to offer advice about LARC methods to a specified proportion of women
attending for contraceptive care to improve contraceptive choice. We examined the impact
and equity of this scheme on LARC uptake and abortions.
Methods and findings
We examined records of 3,281,667 women aged 13 to 54 years registered with a primary
care clinic in Britain (England, Wales, and Scotland) using Clinical Practice Research Data-
link (CPRD) from 2004/2005 to 2013/2014. We used interrupted time series (ITS) analysis
to examine trends in annual LARC and non-LARC hormonal contraception (NLHC) uptake
and abortion rates, stratified by age and deprivation groups, before and after the P4P was
introduced in 2009/2010. Between 2004/2005 and 2013/2014, crude LARC uptake rates
increased by 32.0% from 29.6 per 1,000 women to 39.0 per 1,000 women, compared with
18.0% decrease in NLHC uptake. LARC uptake among women of all ages increased imme-
diately after the P4P with step change of 5.36 per 1,000 women (all values are per 1,000
women unless stated, 95% CI 5.26–5.45, p < 0.001). Women aged 20 to 24 years had the
largest step change (8.40, 8.34–8.47, p < 0.001) and sustained trend increase (3.14, 3.08–
3.19, p < 0.001) compared with other age groups. NLHC uptake fell in all women with a step
change of −22.8 (−24.5 to −21.2, p < 0.001), largely due to fall in combined hormonal contra-
ception (CHC; −15.0, −15.5 to −14.5, p < 0.001). Abortion rates in all women fell immediately
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after the P4P with a step change of −2.28 (−2.98 to −1.57, p = 0.002) and sustained
decrease in trend of −0.88 (−1.12 to −0.63, p < 0.001). The largest falls occurred in women
aged 13 to 19 years (step change −5.04, −7.56 to −2.51, p = 0.011), women aged 20 to 24
years (step change −4.52, −7.48 to −1.57, p = 0.030), and women from the most deprived
group (step change −4.40, −6.89 to −1.91, p = 0.018). We estimate that by 2013/2014, the
P4P scheme resulted in an additional 4.53 LARC prescriptions per 1,000 women (relative
increase of 13.4%) more than would have been expected without the scheme. There was a
concurrent absolute reduction of −5.31 abortions per 1,000 women, or −38.3% relative
reduction. Despite universal coverage of healthcare, some women might have obtained
contraception elsewhere or had abortion procedure that was not recorded on CPRD. Other
policies aiming to increase LARC use or reduce unplanned pregnancies around the same
time could also explain the findings.
Conclusions
In this study, we found that LARC uptake increased and abortions fell in the period after the
P4P scheme in British primary care, with additional impact for young women aged 20–24
years and those from deprived backgrounds.
Author summary
Why was this study done?
• Long-acting reversible contraception (LARC) is more effective and longer lasting than
other methods such as condoms or contraceptive pills at controlling fertility.
• Primary care physicians (PCPs) in Britain were given financial incentives to give infor-
mation on LARC methods to over 90% of women coming for contraceptive advice from
2009/2010.
• We wanted to find out whether this new scheme led to more LARC prescribing and
fewer abortions, signifying fewer unplanned and unwanted pregnancies, particularly in
younger women and those from poorer backgrounds.
What did the researchers do and find?
• We studied health records of over 3 million women aged 13 to 54 years old, from over
600 primary care practices across Britain (England, Wales, and Scotland) from financial
years 2004/2005 to 2013/2014.
• We compared yearly LARC prescriptions and abortions in the years before and after the
LARC advice scheme was introduced in 2009/2010.
• We found 13% more LARC prescriptions and 38% fewer abortions than expected since
the scheme was introduced, particularly in younger women aged 20–24 and those from
poorer backgrounds.
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What do these findings mean?
• Financial incentives for PCPs to give LARC advice to women were associated with more
LARC prescriptions and reductions in abortions.
• The greater impact in younger women and those from more disadvantaged back-
grounds suggests potential to reduce health inequalities by improved awareness of
options for effective fertility control.
Introduction
Unintended pregnancies make up an estimated 44% of all pregnancies worldwide, nearly 60%
of these end in abortions [1], and up to half of unintended pregnancies are due to incorrect or
inconsistent use of contraception [2,3]. Britain has among the highest teenage abortion rates
in Europe [4,5]; together, these suggest significant room for improvement in contraceptive
programmes in Britain and worldwide [6].
Long-acting reversible contraception (LARC) methods include contraceptive injections, sub-
dermal implants, intrauterine devices (IUDs), and the intrauterine systems (IUSs); they offer
continuous contraception from 3 months (injection) to 10 years (IUD). LARCs are reliable,
safe, and more effective at preventing unintended pregnancy compared with combined hor-
monal contraception (CHC) and progestogen-only pills (POP). Therefore, their use is recom-
mended by global programmes and national guidance [7,8]; despite these features, the uptake of
LARC is lower than 15% in many countries [9,10]. Although LARC methods are long-lasting,
those using injection must remember to have it every 12 weeks for continuous contraception.
In Britain, women have access to free contraception, and primary care is the most com-
monly used and preferred setting to obtain contraception [11,12]. In 2004/2005, the British
National Health Service (NHS) introduced radical reforms in primary care through a pay-for-
performance (P4P) scheme that linked primary care practices’ income to performance targets.
A new set of targets were introduced in 2009/2010 that remunerated primary care physicians
(PCPs) to offer full choice of contraception including advice about LARC to women aged 13 to
54 years attending for contraceptive care [13]. Under the scheme, PCPs could offer advice in
verbal or written format and could do so in person, via text message, or letter. Primary care
practices were paid for achieving targets for advice only but not LARC uptake.
The number of LARC items prescribed increased following this scheme, but its impact on
intended outcomes such as LARC uptake and abortion in the population have not been
reported [14]. Our main objective was to examine the impact of a P4P scheme for LARC
advice on LARC uptake and abortion rates in women attending British primary care. Our sec-
ondary objective was to assess the impact of the scheme on LARC uptake and abortions
among young women aged less than 25 years and those from deprived backgrounds, who have
relatively higher abortion rates. We hypothesised that LARC uptake would increase after the
P4P scheme, and that this would lead to reduction in abortions.
Methods
Data source
We used Clinical Practice Research Datalink (CPRD), a database of anonymised electronic
health records extracted from over 600 primary care practices in Britain (i.e. England,
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Scotland, and Wales). It has a coverage of over 17 million registered patients broadly represen-
tative of age, sex, and ethnicity of approximately 7% of the British population [15].
Population
We extracted records for women aged 13 to 54 years, which was the target age range for the
P4P scheme. For each financial year (1 April to 31 March the following year) from 2004/2005
to 2013/2014, we included women in the denominator if they were registered with a primary
care practice at any point that year that was deemed “up to standard” (when the practice met
data quality and completeness criteria) in the previous year. The population was an open
cohort, and new women were added to the denominator population each year. Women
became eligible when they turned 13 in any study year; conversely, women who turned 55
were censored, as were any who died, or if their practice stopped contributing data to CPRD.
We assigned women to one of 4 age groups: 13 to 19, 20 to 24, 25 to 34, and 35 to 54 years;
women could pass across age groups over the study period. Women were assigned to one of 5
population-weighted deprivation groups based on their residential post code using English
Indices of Multiple Deprivation (IMD) quintiles that range from IMD 1 (least deprived) to
IMD 5 (most deprived). The IMD is a weighted combination measure of deprivation using 38
separate indicators across 7 distinct domains identified in the English Indices of Deprivation:
deprivation, employment deprivation, health deprivation and disability, education skills and
training deprivation, barriers to housing and services, living environment deprivation, and
crime; IMD data are available for English populations only [16]. The postcode used to derive
deprivation groups is unique for women in the cohort during the time they were registered to
the practice. When the patient moved and registered with a new practice, that individual was
censored from the previous practice.
Every woman between the ages of 13 and 54 registered with a practice for any part of the
financial year was potentially “at risk” of unplanned pregnancy. We used this definition as it
was consistent with the denominator defined as eligible for LARC advice in the P4P scheme.
Outcomes
Our main outcome was annual LARC uptake, calculated by summing the total number of
women who chose any LARC method divided by the number of women registered in the
denominator that financial year, expressed as per 1,000 women aged 13–54 years. We defined
LARC as any branded or generic prescriptions of contraceptive injections, implants, IUSs, and
IUDs. All other branded or generic prescriptions of CHCs (including pills, vaginal rings, and
patches) and POPs were grouped as non-LARC hormonal contraception (NLHC). We
reported both NLHC and LARC prescriptions to examine overall contraceptive uptake and
changes in method preference over the years.
Given that our main aim was to evaluate impact of a P4P on LARC uptake, we only
recorded whether LARC was prescribed at all for each woman in any given year, rather than
quantifying the number of such prescriptions. LARC methods such as implants and IUDs last
from 3 to 10 years and so were prescribed infrequently, whereas injections and NLHC were
prescribed several times a year. Therefore, for fairer comparison, we counted only the incident
prescription of either a LARC or NLHC per woman per year, whichever was prescribed first. If
women were prescribed more than one LARC product, we counted only the first product that
year.
Our secondary outcome measure was annual abortion rates, defined as the number of abor-
tions divided by denominator count, expressed as per 1,000 women aged 13–54 years. We
used abortion as a proxy measure of unplanned and unwanted pregnancy; notwithstanding
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the limitations, we hypothesised this would be reduced if more women chose to use more
effective LARC methods.
Women in Britain are referred for an abortion through their PCP, hospital, or sexual health
clinic; they can also self-refer in some areas. Women may also withhold consent for informa-
tion to be sent back to their PCP; for this reason and to minimise missing data, we compiled a
list that included both referral and procedure codes for abortions.
Our analysis focused on Britain (i.e., England, Scotland, and Wales) rather than the whole
of the United Kingdom as access to abortion was restricted in Northern Ireland during the
study period. Women often travelled to Britain to have an abortion privately, which renders
Northern Ireland’s abortion figures unreliable. Women may have more than 1 abortion in any
year, but we counted only the earliest event if there were 2 or more recorded within 6 weeks of
another to be biologically plausible.
We calculated annual rates for LARC, NLHC, and abortion and performed subgroup analy-
ses by age and deprivation.
Statistical analysis
We examined outcomes using interrupted time series (ITS) analysis to compare trends in
annual contraceptive uptake and abortion rates before and after the introduction of the P4P in
financial year 2009/2010. ITS analysis is a strong quasi-experimental research design often
used to evaluate impact of natural experiments such as health policy changes at a population
level [17].
We used a segmented time series regression model for analysis. The regression is repre-
sented by S1 Fig and the formula outcomejt = β0+β1�timet+β2�levelj+β3�trendjt+εjt. Any out-
come of intervention status j at time t is a product of 4 variables: the existing level β0 at time 0;
β1 represents the trend at time t; β2 is the step change in level for intervention j; β3 represents
the trend line at time t for intervention j; with additional error terms for that time and
intervention.
To model possible long-term seasonal patterns, the data were “time stratified” by year,
which permitted adjustment for confounding by “seasonality.” We used 5 time points for the
pre-intervention phase from 2004/2005 to 2008/2009; we excluded data for 2009/2010 in the
analysis to allow for a 1-year “phase-in period” for the scheme to take effect, followed by 4
time points after the phase-in period from 2010/2011 to 2013/2014. To account for auto-corre-
lated data, we used autoregressive moving average (ARMA) models [18]. The order of the
moving average and the autoregressive model parameters were determined using multiple
methods, including scatter plots of the deviance residuals versus time, the Durbin–Watson
test, and the autocorrelation and partial autocorrelation functions [17,19,20]. We used the
maximum likelihood ratio test to assess the fit of the model parameters. We used the General-
ised Least Squares (GLS) approach to run the final model, which is like a linear regression but
allowed autoregressive and moving average processes.
We used the final model to estimate the absolute and relative changes in 2013/2014, i.e., 4
years after the P4P scheme was introduced, by calculating the differences between the counter-
factual (which is an extension of the pre-P4P trendline) and fitted model (post-P4P trendline)
at that time point. There are no precision parameters for these because they are derived from
the modelled trends, which already have their confidence intervals.
Sample size
Population studies suggest that the lowest prevalence of LARC use was 1 per 1,000 for intra-
uterine device (IUD) in women of reproductive ages [9,10]; an increase of 15% is both
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clinically significant and likely, given that previous studies reported a range of 6%–20% [14]. A
sample size of 1,016,000 women before and after intervention would be adequate to detect an
increase in proportion from 1 in 1,000 to 1.15 in 1,000 with 90% power at 5% significance
level.
Sensitivity analysis
Although the incentive was introduced in financial year 2009/2010, we allowed one full finan-
cial year for it to be fully implemented (“phase-in period”); this gave women time to respond
to advice and start or switch to LARC. We compared the trends in crude contraceptive pre-
scription and abortion rates with (5 time points before, 1 year of “phase-in,” and 4 time points
after) and without phase-in period (5 time points before the intervention and 5 time points
after).To demonstrate the time taken to fully implement the P4P scheme, we calculated the
proportion of eligible women based on the P4P scheme (those prescribed NLHC) given LARC
advice per financial year from 2004/2005 to 2013/2014.
Women have been able to self-refer for abortions without having to see their PCP. They
also could withhold consent for the clinic to inform their PCP of the abortion procedure. To
examine the impact of missing abortion events, we conducted a sensitivity analysis to examine
the effect of adding 20%, 40%, and 50% extra abortion events after the P4P scheme.
We used STATA version 14 (STATA Corp, College Station, TX) to perform the data man-
agement. We used R Studio (Version 1.1.456–2009–2018 RStudio; http://www.r-project.org)
for modelling and statistical tests.
Patient and public involvement
This research has involved views of the public throughout; this included informal engagement
on social media at the time of RM’s doctoral fellowship proposal, and then more formally
through a Project Advisory Group (PAG) that meets twice a year to discuss the programme of
research during the fellowship. Membership of PAG includes individuals, professionals, and
charity representatives in the sexual and reproductive healthcare sector. Members’ contribu-
tions have included lay summaries, helping with sensitive use of language, framing, interpreta-
tion, reporting, and dissemination of study findings.
Ethical approval
The CPRD has obtained ethical approval from the UK’s National Research Ethics Service
(NRES) Committee for observational research using anonymised data. The study protocol was
approved by the Independent Scientific Advisory Committee (ISAC) for Medicines and
Healthcare Products Regulatory Agency (MHRA) database research (protocol number 15/
076_R2, S1 File).
Results
Our study population included 3,281,667 women aged 13 to 54 years from over 600 practices
across Britain from 2004/2005 to 2013/2014. The total eligible population, and the relative pro-
portions by age group, region, and deprivation groups for each financial year, were broadly
stable across the study period (S2–S4 Figs). There was a 12.9% attrition in the annual denomi-
nator population from 1,117,648 in 2004/2005 to 973,473 in 2013/2014 (Table 1) due to
reduced number of practices contributing to CPRD as several practices switched software sys-
tems in a few of regions in England (North East, Yorkshire and Humber and East Midlands).
Practice populations in the South of England and more affluent postcodes were
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overrepresented. LARC advice was offered to 43.4% of eligible women in 2004/2005, rising to
78.3% in 2008/2009 and then 95.3% when the P4P was introduced in 2009/2010; this propor-
tion was sustained between 96.5% and 97.9% by the end of the study period, which supported
the use of a phase-in period in 2009/2010 (S1A Table).
Trends in LARC uptake
Between 2004/2005 and 2013/2014, crude LARC uptake rates increased by 32.0% from 29.6 to
39.0 per 1,000 women, compared with a smaller increase (18.0%) from 172 to 203 per 1,000
women in NLHC uptake (Table 1 and Fig 1). Crude LARC uptake increased in all age groups
from 2004/2005 to 2013/2014, but the relative change was greatest in women aged 35 to 54
years (48.1%), followed by 13 to 19 years (32.1%), 20 to 24 years (19.1%), and 24 to 34 years
(18.6%). Crude LARC uptake was higher in women from most deprived than least deprived
group throughout the study period, but relative increase in uptake was larger in least deprived
(43.6%) compared with the most deprived (13.9%) group (Table 1, S5 Fig). Among the LARC
methods, the contraceptive injection had the greatest uptake across the study period, but crude
rates fell by 5.4% from 22.2 in 2004/2005 to 21.0 in 2013/2014; there was also a fall in IUD
uptake by 8.5%. There was an 8-fold increase in crude uptake rate of contraceptive implants
and a smaller rise in IUS uptake (86.0%) (S1B Table).
ITS analysis (Table 2) showed a small increase in trend (0.56, 0.54–0.59, p< 0.001) in
LARC uptake rate in all ages before the P4P, and then an increase immediately after the P4P
was introduced (5.36, 5.26–5.45, p< 0.001), followed by a small but sustained decrease in
trend 4 years following the P4P (−0.35, −0.42 to −0.28, p< 0.001). All LARC methods had sta-
tistically significant and positive step changes in uptake immediately after the P4P; the greatest
step changes occurred in injection (1.68, 1.67–1.70, p< 0.001) and implant (1.64, 1.63–1.65,
Table 1. Crude rates per 1,000 women for LARC, NLHC uptake, and abortion by age and deprivation groups at 3 time points: Study baseline (2004/2005), introduc-
tion of P4P scheme in 2009/2010, and end of study (2013/2014).
Variable LARC NLHC Abortions
Year 2004/2005 2009/2010 2013/2014 2004/2005 2009/2010 2013/2014 2004/2005 2009/2010 2013/2014
All ages 1,117,648 1,156,125 973,473 1,117,648 1,156,125 973,473 1,117,648 1,156,125 973,473
29.6 33.9 39.0 172 208 203 16.9 13.9 8.59
Age group (years)
13–19 159,368 163,444 139,621 150,646 163,444 139,621 150,646 163,444 139,621
20.9 24.0 27.6 197 223 205 26.6 18.1 7.66
20–24 107,921 113,168 97,039 103,018 113,168 97,039 103,018 113,168 97,039
52.9 52.4 63.0 393 434 396 57.5 44.4 23.8
25–34 252,564 253,811 222,146 253,424 253,811 222,146 253,424 253,811 222,146
45.7 47.8 54.2 291 343 323 25.2 22.7 15.8
35–54 629,744 625,702 514,667 610,560 625,702 514,667 610,560 625,702 514,667
21.0 27.4 31.1 79.1 108 114 4.17 3.63 2.85
Deprivation� group
Least deprived 161,781 177,608 141,254 161,781 177,608 141,254 161,781 177,608 141,254
22.0 25.9 31.6 166 210 207 12.1 9.12 4.96
Most deprived 106,615 120,866 98,300 106,615 120,866 98,300 106,615 120,866 98,300
42.4 44.4 48.3 161 192 172 26.5 20.6 12.9
�Deprivation data available for England only.
Denominators are given in italics and rate per 1,000 women in bold.
Abbreviations: LARC, long-acting reversible contraception; NLHC, non-LARC hormonal contraception; P4P, pay for performance
https://doi.org/10.1371/journal.pmed.1003333.t001
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p< 0.001). There was a reversal in the trend of contraceptive injection uptake from an initial
decline pre-P4P (−0.86, −0.86 to −0.85, p< 0.001), step change increase (1.68,1.67–1.70, p<
0.001), followed by a sustained increase post-P4P (1.25, 1.24–1.27, p< 0.001).
There were statistically significant step increases in LARC uptake across all ages. The great-
est rise occurred among women aged 20–24 years (8.40, 8.34–8.47, p< 0.001), with sustained
increase in uptake in the 4 years after the introduction of the P4P (3.14, 3.08–3.19, p< 0.001).
There was a small increase in the trend in LARC uptake in women from least deprived group
pre-P4P (0.10, 0.10–0.10, p< 0.001), whereas the trend pre-P4P was decreasing in the most
deprived group (−0.03, −0.06 to −0.01, p = 0.041). Immediately after the P4P there was greater
step change in LARC uptake in the least deprived (5.71, 5.70–5.71, p< 0.001) compared with
the most deprived group (3.72, 3.61–3.83, p< 0.001).
Our model estimated that 4 years after the P4P scheme, there were an additional 4.53
LARC prescriptions per 1,000 women, more than would have been expected had the P4P
scheme not been introduced. This represents a relative increase of 13.4%.
Trends in NLHC uptake
NLHC use was highest in women aged 20 to 24 years compared with other age groups and
higher among women from the most affluent compared with the most deprived group
Fig 1. Summary figure. Trends in crude LARC and NLHC uptake and abortion rates between 2004/2005 and 2013/2014 in women aged 13–54 years in British primary
care before and after introduction of P4P scheme for LARC advice. AD, absolute difference; LARC, long-acting reversible contraception; NLHC, non-LARC hormonal
contraception; P4P, pay for performance; RD, relative difference.
https://doi.org/10.1371/journal.pmed.1003333.g001
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(Table 1 and Fig 1). The rise in NLHC use across the study period was highest among women
aged 35 to 54 years (44.1%) and more affluent women (24.7%) (S6 Fig).
The ITS analysis showed an increasing trend in NLHC uptake (9.25, 8.98–9.52, p< 0.001)
pre-P4P, a step change of −22.9 (−24.5 to −21.2, p< 0.001), and a sustained decrease in trend
Table 2. ITS analysis of trends in contraceptive uptake rate per 1,000 women in primary care in Britain before and after introduction of P4P scheme in 2009/2010.
Pre-P4P trend Step change Post-P4P trend Rate change/1,000 women 4 years
after P4P






LARC All ages 0.56 (0.54 to 0.59) 5.36 (5.26 to 5.45) −0.35 (−0.41 to
−0.28)
4.53 13.4
Injection All ages −0.86 (−0.86 to
−0.85)
1.68 (1.67 to 1.70) 1.25 (1.24 to 1.27) 5.83 38.0
Implant All ages 0.71 (0.71 to 0.71) 1.64 (1.63 to 1.65) −0.20 (−0.21 to
−0.18)
1.57 24.8
IUD All ages −0.04 (−0.04 to
−0.04)
0.21 (0.20 to 0.22) 0.00 (0.00 to
0.01)1
0.18 10.1
IUS All ages 0.51 (0.51 to 0.52) 0.95 (0.95 to 0.96) −0.54 (−0.55 to
−0.54)
−0.70 −8.03
All LARC methods 13–19 y 0.15 (0.09 to 0.22)2 4.51 (4.18 to 4.83) 1.04 (1.00 to 1.08) 8.83 42.3
20–24 y −0.90 (−0.91 to
−0.88)
8.40 (8.34 to 8.47) 3.14 (3.08 to 3.19) 20.1 45.1
25–34 y −0.50 (−0.50 to
−0.49)
6.31 (6.28 to 6.34) 1.40 (1.37 to 1.42) 11.4 26.9
35–54 y 0.99 (0.99 to 1.00) 2.27 (2.25 to 2.29) −0.52 (−0.54 to
−0.50)
1.19 4.01
Least deprived 0.10 (0.10 to 0.10) 5.71 (5.70 to 5.71) 0.48 (0.48 to 0.48) 7.73 33.0
Most deprived −0.03 (−0.06 to
−0.01)3
3.72 (3.61 to 3.83) 0.67 (0.58 to 0.76) 6.37 15.2

















































Abbreviations: CHC, combined hormonal contraception; ITS, interrupted time series; IUD, intrauterine device; IUS, intrauterine system; LARC, long-acting reversible
contraception; NLHC, non-LARC hormonal contraception; P4P, pay for performance; POP, progestogen-only pill.
https://doi.org/10.1371/journal.pmed.1003333.t002
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of −7.10 (−7.88 to −6.33, p< 0.001) in NLHC uptake overall (Table 2). We observed a similar
pattern among different NLHC methods (CHC and POP), all age groups, and deprivation
quintiles.
By the end of the study period in 2013/2014, there was an overall fall in NLHC uptake of
−42.0 per 1,000 women (−16.9%) compared with what would have been expected if the P4P
scheme had not been introduced; this was mostly accounted for by falls in CHC uptake.
Trends in abortion
Crude abortion rates fell by 49.2% from 16.9 to 8.59 across the study period (Table 1 and Fig
1); the biggest falls occurred in teenage women (−71.2% in those aged 13 to 19 years versus
−31.7% in women aged 35 to 54 years S7 Fig). Falls in abortion rates were greater in women
from least deprived compared with most deprived group (−59.0% versus −51.3%).
Trends in abortion rates in all ages were decreasing (Table 3) pre-P4P (−0.41, −0.55 to
−0.27, p = 0.002); this was followed by a step change of −2.28 (−2.99 to −1.57, p = 0.002) imme-
diately after the P4P was introduced and further sustained decreases in trends post-P4P
(−0.88, −1.12 to −0.63, p< 0.001). There was an absolute reduction of −5.31 abortions per
Table 3. Summary of ITS analysis of trends in abortion rates before and after introduction of P4P scheme in 2009/2010 in primary care practices in Britain.
Abortion rates per 1,000
women
Pre-P4P trend Change in level Post-P4P trend Rate change 4 years after
P4P
% change 4 years after
P4P




−0.88 (−1.12 to −0.63) −5.31 −38.3
Age group (years)












25–34 −0.16 (−0.39 to 0.07)7 −2.15 (−3.34 to
−0.97)8
−1.54 (−1.95 to −1.14) −8.49 −35.1
35–54 −0.09 (−0.14 to 0.04)9 −0.17 (−0.42 to 0.07)10 −0.13 (−0.22 to
−0.04)11
−0.66 −19.2
Least deprived −0.40 (−0.47 to −0.32) −1.36 (−1.72 to −1.01) −0.73 (−0.86 to −0.61) −3.96 −44.0




−0.74 (−1.60 to 0.13)14 −7.46 −37.5















Abbreviations: ITS, interrupted time series; PHP, pay for performance
https://doi.org/10.1371/journal.pmed.1003333.t003
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1,000 women (relative reduction of −38.3%) in all ages compared with what would have been
expected without the P4P scheme; this is equivalent to 95,170 additional abortions averted by
2013/2014 if extrapolated to the British population.
The greatest impact of the P4P policy on abortion rates occurred in women under 25 years.
Women aged 13–19 had the largest step change (−5.04, −7.56 to −2.51, p = 0.011) followed by
sustained decrease in trend of −1.19 (−2.07 to −0.32, p = 0.044) (Table 3). Women aged 20 to
24 years had step change of −4.52 (−7.48 to −1.57, p = 0.030) immediately after the P4P, fol-
lowed by sustained decrease in trend in the 4 years post-P4P (−2.84, −3.84 to −1.84, p = 0.003).
Abortion rates fell more among women from the most deprived group compared with those
in the least deprived group immediately after the P4P (step change −4.40 versus −1.36). Abor-
tion rates continued to fall post-P4P in all groups; the relative change in women from the least
deprived group were greater (−44.0% least deprived versus −37.5% most deprived).
Sensitivity analysis
Phase-in periods did not alter the trends of LARC uptake and abortion rates, but the associa-
tion was greater with than without (S1C Table). For LARC uptake, the step change was 5.36
(5.26–5.45, p< 0.001) with the phase-in period and 3.34 (3.17–3.52, p< 0.001) without. The
association with NLHC was greater; step change in NLHC was −22.9 (−24.5 to −21.2, p<
0.001) with phase in and −8.01 (−9.09 to −6.92, p< 0.001) without phase in. The step change
in abortion rates associated with the P4P was greater with phase in (−2.28, −2.99 to −1.57, p =
0.002) than without (−1.49, −1.62 to −1.35, p< 0.001).
In our sensitivity analysis, we found a sustained reduction in abortion rates post-P4P under
all 3 scenarios of missing data on abortion: 20%, 40%, or 50%, all of which were statistically sig-
nificant (p< 0.001, S1D Table). Even if 50% additional abortion events were included in the
analysis after the P4P, the trend post-P4P would have been −1.52 (1.78 to −1.26, p< 0001).
Discussion
Main findings
Our study showed a 13.4% increase in LARC uptake following the P4P scheme. This increase
was unlikely to be related to a general increase in contraceptive uptake as we demonstrated a
concomitant relative reduction of −16.9% in NLHC uptake in the same period. We also report
a −38.3% reduction in the abortion rate compared with what would have been expected with-
out the P4P scheme for LARC advice.
Young women aged 20 to 24 years increased their uptake of LARC the most, while those
aged 13 to 19 years had the largest fall in abortion rates compared with other age groups.
Women from the most deprived group had the largest decrease in abortion rates immediately
following the P4P scheme. Overall, the P4P scheme had the biggest impact on younger women
and those from the most deprived backgrounds.
Comparison with current literature
The prevalence of contraceptive uptake in different age groups is consistent with findings
from comparable surveys. The prevalence of oral contraceptive pill use in 2008/2009 was 54%
in women aged 20–24 years and 10% in 40–49 years in one survey, compared with 44% (442
per 1,000 women) using NLHC among women aged 20–24 years and 11% (106 per 1,000
women) in women aged 35–54 years, respectively, in our study (S6 Fig) [21]. In a large proba-
bility sample survey conducted in 2010 to 2012, 26% of women aged 16 to 24 were using hor-
monal methods (defined in the study as patches, pills, and injections), and 11% used LARC
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(implant, IUD, IUS) [22]. In our study, age-specific NLHC rates in 2011/2012 were 21% for
women aged 13 to 19 and 41% for women aged 20 to 24. Age-specific rates for LARC in 2011/
2012 were 3% in women aged 13 to 19 and 6% in women aged 20–24 (S5 Fig). Our previous
study examining P4P policy impact using dispensing data reported similar trends and patterns
in individual LARC prescriptions [14].
Trends in abortion rates were similar to those from national surveillance records for
England and Wales, which showed that the 20–24 age group had the highest crude age-specific
rate (30.0 per 1,000 women) of all age groups in 2009; our data also showed this age group had
the highest rates (44.6) among all ages in 2009/2010 (we used England and Wales data only for
this comparison) [23]. The crude abortion rate in women under 18 years was 11.7 in 2013,
which was a 33.5% reduction from 17.6 in 2009; our data showed a much greater reduction
from 18.3 in 2009/2010 to 7.50 in 2013/2014 (59%) for ages 13 to 19 years (England and Wales
data). Our study population of 3.2 million women with prospectively collected data is likely to
provide a more accurate estimate than surveys based on self-reporting, and—as this is a popu-
lation of women who engaged with primary care services in Britain—it would make sense that
these women benefited more from interactions with their PCP.
Strengths and limitations
To our knowledge, this is the first national evaluation of the impact of the contraceptive P4P
scheme in Britain. Our large sample size from the CPRD database greatly enhances the repre-
sentativeness of our findings to the British population and comparable middle- to high-income
countries. Many previous studies on P4P schemes reported processes of care and not out-
comes; even those that reported outcomes did not demonstrate long-term sustainability
[24,25]. Ours is one of few that has demonstrated changes in both clinical process and patient
outcomes in relation to one P4P scheme as well as sustainability for at least 4 years after its
introduction. To strengthen our methodology, we used at least 3 time points before and after a
clearly defined intervention period; we used an ARMA model for analysis; we conducted auto-
correlation and sensitivity analysis; and we adhered to the recommended reporting framework
for ITS studies to improve reporting and enable comparisons in systematic reviews (S2 File)
[26].
However, there are important limitations of our study that relate to our design, accuracy,
and completeness of data. The CPRD database might have a relatively good coverage of the
population in Britain, but it is not a random sample: 5 out of 12 regions are overrepresented in
the population, so there might be selection bias from the types of practices that contributed to
the database (S3 Fig). Despite this, our population in 2004/2005 and 2013/2014 closely
matched the age distributions of the mid-year UK census populations (S8 Fig). Another bias is
that deprivation data were only available for the English population; we found a relatively
larger number of women in the least deprived group (IMD 1), and this distribution of IMD
was the same throughout the study period (S4 Fig). We cannot comment from our data and
methodology on whether women from more deprived areas were targeted for LARC advice.
We only counted incident contraceptive prescriptions that might have underestimated
NLHC methods as they had to be prescribed relatively more frequently due to their shorter
duration of action; however, this was offset by the several-fold difference in volume of NLHC
prescriptions compared with LARC. The use of prescription data also meant we could not
draw conclusions about women who were sexually active but who were using methods that
could not be prescribed, or nothing at all as they might be pregnant or trying to conceive.
Additionally, data completeness might be threatened by missing events and patients, mis-
classification, and miscoding of clinical events, especially abortions by PCPs; event data might
PLOS MEDICINE Pay-for-performance scheme for long-acting reversible contraceptive (LARC) advice in British primary care
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003333 September 14, 2020 12 / 18
be missing if abortion procedures were not reported back to the PCP. Nevertheless, we have
demonstrated the prevalence of our outcome measures matched closely with those from other
sources. The sensitivity analysis has demonstrated the reduction in abortion rates after the P4P
scheme was still significant even if we added 50% additional events to the modelling.
There might also be missing data on NLHC and LARC as women obtain contraceptive care
from sexual health clinics. While this might explain the low numbers of IUDs as more might
be fitted in community contraceptive clinics, it would not explain the rise in IUSs or con-
traceptive implants. As we were interested in the impact of primary care interactions on con-
traceptive uptake and abortions, the main emphasis was on data recorded in primary care.
There might be overestimation of IUSs because of their use in managing heavy menstrual
bleeding; while this might have explained the higher prevalence of use in older women (just
over 50% of our sample aged 35 to 54), it is unlikely to have had significant impact on the over-
all findings.
Scatter plots of crude rates before and after the interventions for all outcome measures sug-
gested that linear modelling was the best approach, and this assumption was applied when cal-
culating the difference between fitted models and the counterfactual. All predictive modelling
is subject to a degree of uncertainty, so our predicted changes should be interpreted with
caution.
Other interventions around the same time as introduction of the P4P could have affected
validity of ITS analysis. Two important events might be relevant: firstly, national clinical guid-
ance on LARC was published by National Institute for Health and Care Excellence (NICE) in
2005 at the start of the study period, which might have contributed to increasing awareness of
LARC for clinicians and the public. Secondly, media campaigns to improve awareness of con-
traception and LARC among young people were introduced in November 2009; however, this
only ran for a month, and it was unlikely that the impact lasted as long as the end of our study
period in 2013/2014 [27]. In addition, the Teenage Pregnancy Strategy was introduced in
England in 1999, and the policy was implemented for 10 years [28]; emergency hormonal con-
traception had been made available free of charge in Scotland from 2008 and in Wales in 2011,
which could also contribute to reducing unplanned pregnancies [29,30]. However, our study
design shows additional impact of the P4P scheme over underlying trends and in other age
groups.
Implications for policy and research
The rationale from policy makers for including LARC advice as part of the primary care P4P
scheme was to ensure that women were informed of contraceptive choices to best meet their
needs and also an assumption that “increasing the uptake of LARC methods will reduce the
number of unintended pregnancies” [13]. The implications from our study suggest that offer-
ing financial incentives to PCPs to give LARC advice to women not only increased the uptake
of LARC but also reduced abortion rates. The study outcome seemed to confirm our hypothe-
sis. We speculate the mechanism for increasing LARC uptake might be that LARC advice from
PCPs facilitated switching from NLHC to more reliable methods, such as LARC for some
women, which in turn prevented more unintended pregnancies.
If these changes in contraceptive uptake and abortions occurred because of the P4P, we esti-
mate that by 2013/2014, the P4P scheme resulted in an additional 4.53 LARC prescriptions per
1,000 women or relative increase of 13.4%, equivalent to 81,190 extra prescriptions if extrapo-
lated to the British population. There was an absolute reduction of −5.31 abortions per 1,000
women, or −38.3% relative reduction, equivalent to 95,170 abortions averted if extrapolated to
the British population.
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There have been discussions in British primary care that the P4P scheme that has been run-
ning for over 15 years might be abolished [31]. The scheme attracted much discussion on the
best ways to remunerate PCPs to deliver good quality care, what the intended consequences
were, and the erosion of the patient’s agenda in the consultation [32–34]. Our study suggests
there might be merit in retaining this scheme to support primary care to improve reproductive
health outcomes. More recently, a study found that removal of some P4P indicators in British
primary care was associated with decline in performance, quality, and documentation, includ-
ing LARC advice [35]. An extension of our study for a longer period might yield answers
regarding impact on reproductive outcomes—whether the effects on these might be sustained
after removal of this P4P scheme.
As this is an ecological study, we are unable to comment on the causal pathway at the indi-
vidual level. We are unable to comment about whether women switched from NLHC in favour
of LARC because the latter were more desirable, more effective, safer (e.g., IUD is hormone-
free, so reduced cardiovascular risks associated with oestrogens) or because they became better
informed about options available to them. Future studies should examine the impact of LARC
advice on contraceptive uptake and choice of individual women, which women responded to
LARC advice, and the effect of LARC uptake on the risk of unintended pregnancy outcomes.
There might also be policy differences among Scotland, England, and Wales that could be
examined.
There are different opinions about what the best strategies should be at the population level
to reduce unplanned and unwanted pregnancies. It has been estimated that more unintended
pregnancies would be prevented by increasing the number of contraceptive users overall,
rather than encouraging use of a specific methods [36,37]. Financial incentives, target-driven
programmes, and strategies that focus on certain demographic subgroups might be effective
but may be seen as coercive, particularly if LARC is promoted over other methods [38]. While
we need to carefully consider women’s reproductive autonomy over promotion of LARC
methods, these discussions do not diminish the importance of reducing barriers to LARC use
for deprived populations [39].
At the individual level, LARC is not necessarily suitable for all women because it can have
unwanted effects, and method preference will be based on a balance between reliability for
long-acting methods and autonomy for short-acting methods. Some women may also use con-
traceptive methods for other indications, for example, some CHCs can be used to treat acne,
IUS is licensed to treat heavy menstrual bleeding. The underlying principle of fertility control
programmes should ensure women are fully informed about the range of contraceptive
options so that they can make a choice fitting their needs and preferences and appropriate for
their stage of life.
Conclusions
Our study offers evidence that the P4P scheme to give LARC advice in primary care was fol-
lowed by increased LARC uptake and falls in abortion rates. This scheme had greater impact
on younger women and those from more deprived quintiles compared with all other groups.
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